8 research outputs found
Kynurenic Acid Is a Potent Endogenous Aryl Hydrocarbon Receptor Ligand that Synergistically Induces Interleukin-6 in the Presence of Inflammatory Signaling
Inflammatory signaling plays a key role in tumor progression, and the pleiotropic cytokine interleukin-6 (IL-6) is an important mediator of protumorigenic properties. Activation of the aryl hydrocarbon receptor (AHR) with exogenous ligands coupled with inflammatory signals can lead to synergistic induction of IL6 expression in tumor cells. Whether there are endogenous AHR ligands that can mediate IL6 production remains to be established. The indoleamine-2,3-dioxygenase pathway is a tryptophan oxidation pathway that is involved in controlling immune tolerance, which also aids in tumor escape. We screened the metabolites of this pathway for their ability to activate the AHR; results revealed that kynurenic acid (KA) is an efficient agonist for the human AHR. Structure-activity studies further indicate that the carboxylic acid group is required for significant agonist activity. KA is capable of inducing CYP1A1 messenger RNA levels in HepG2 cells and inducing CYP1A-mediated metabolism in primary human hepatocytes. In a human dioxin response element–driven stable reporter cell line, the EC25 was observed to be 104nM, while in a mouse stable reporter cell line, the EC25 was 10μM. AHR ligand competition binding assays revealed that KA is a ligand for the AHR. Treatment of MCF-7 cells with interleukin-1β and a physiologically relevant concentration of KA (e.g., 100nM) leads to induction of IL6 expression that is largely dependent on AHR expression. Our findings have established that KA is a potent AHR endogenous ligand that can induce IL6 production and xenobiotic metabolism in cells at physiologically relevant concentrations
Estrogen Receptor Expression Is Required for Low-Dose Resveratrol-Mediated Repression of Aryl Hydrocarbon Receptor Activity
The putative cardioprotective and chemopreventive properties of the red wine phenolic resveratrol (RES) have made it the subject of a growing body of clinical and basic research. We have begun investigations focusing on the effects of RES on the activity of the aryl hydrocarbon receptor (AHR) complex. Our evidence suggests that RES is a potent repressor of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-inducible gene transcription in estrogen receptor (ER)-positive human breast, lung, and colon cancer cell lines. RES activates the transcription of the ER target genes to the same degree as estradiol (E2) in human MCF-7 breast cancer cells. Unlike E2, which can only diminish TCDD-inducible CYP1A1 gene transcription by approximately 50%, RES can completely abrogate this response. Furthermore, 50% repression of TCDD-inducible transcription can be achieved with 100 nM RES, approximately 2.5 orders of magnitude lower than concentrations required for maximal inhibition, suggesting that multiple mechanisms are responsible for this effect. RES (100 nM) does not prevent ligand binding of a TCDD analog, nor does it prevent AHR from binding to its response element in the 5′-regulatory region of the CYP1A1 gene. Small inhibitory RNAs directed to ERα have demonstrated that RES-mediated repression of CYP1A1 depends on ERα. Whereas CYP1A1 protein levels in MCF-7 cells are refractory to the low-dose transcriptional effects of RES, a concomitant decrease in CYP1A1 protein levels is observed in Caco-2 cells. These results highlight a low-dose RES effect that could occur at nutritionally relevant exposures and are distinct from the high-dose effects often characterized
Antagonism of Aryl Hydrocarbon Receptor Signaling by 6,2′,4′-TrimethoxyflavoneS⃞
The aryl hydrocarbon receptor (AHR) is regarded as an important homeostatic
transcriptional regulator within physiological and pathophysiological processes,
including xenobiotic metabolism, endocrine function, immunity, and cancer. Agonist
activation of the AHR is considered deleterious based on toxicological evidence
obtained with environmental pollutants, which mediate toxic effects through AHR.
However, a multitude of plant-derived constituents, e.g., polyphenols that exhibit
beneficial properties, have also been described as ligands for the AHR. It is
conceivable that some of the positive aspects of such compounds can be attributed to
suppression of AHR activity through antagonism. Therefore, we conducted a dioxin
response element reporter-based screen to assess the AHR activity associated with a
range of flavonoid compounds. Our screen identified two flavonoids (5-methoxyflavone
and 7,4′-dimethoxyisoflavone) with previously unidentified AHR agonist
potential. In addition, we have identified and characterized
6,2′,4′-trimethoxyflavone (TMF) as an AHR ligand that
possesses the characteristics of an antagonist having the capacity to compete with
agonists, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin and
benzo[a]pyrene, thus effectively inhibiting AHR-mediated
transactivation of a heterologous reporter and endogenous targets, e.g., CYP1A1,
independent of cell lineage or species. Furthermore, TMF displays superior action by
virtue of having no partial agonist activity, in contrast to other documented
antagonists, e.g., α-napthoflavone, which are partial weak agonists. TMF
also exhibits no species or promoter dependence with regard to AHR antagonism. TMF
therefore represents an improved tool allowing for more precise dissection of AHR
function in the absence of any conflicting agonist activity
Protein function analysis: rapid, cell-based siRNA-mediated ablation of endogenous expression with simultaneous ectopic replacement
Current methods for determining and dissecting the function of a specific protein within a cell are laborious and limiting. We have developed a method by which endogenous protein levels are rapidly ablated and simultaneous expression of a designed, inserted variant takes place in the native setting. Through optimized electroporation, siRNA oligonucleotides and codon-optimized coding sequence containing vectors can be co-transfected, leading to expression of ectopic mRNA not targeted by siRNA. Using the commonly encountered MCF-7 breast cancer cell line, we were able to reach 90% transfection efficiency. Under these conditions, siRNA oligonucleotides were transfected simultaneously with a codon-optimized, cDNA containing vector encoding the AHR protein. Thus, endogenous protein was ablated while the designed protein was fully expressed in the native environment. The codon-optimized AHR was shown to be fully functional in its ability to induce CYP1A1 transcription and to rescue a B[a]P-susceptible phenotype